Abstract The ability of engineered antibodies to rapidly and selectively target tumors that express their target antigen makes them well suited for use as radioimaging tracers. The combination of molecular size and bivalent nature makes diabody molecules a particularly promising structure for use as radiotracers for diagnostic imaging. Previous data have demonstrated that the anti-HER2 C6.5 diabody (C6.5db) is an effective radiotracer in preclinical models of HER2-positive cancer. The aim of this study was to evaluate the impact on radiotracer performance, associated with expressing the C6.5db in the Pichia pastoris (P-C6.5db) system as compared to Escherichia coli (E. C6.5db). Glycosylation of P-C6.5db led to faster blood clearance and lower overall tumor uptake than seen with E. coli-produced C6.5db. However, P-C6.5db achieved high tumor/background ratios that are critical for effective imaging. Dosimetry measurements determined in this study for both 124 I-P-C6.5db and 124 I-E-C6.5db suggest that they are equivalent to other radiotracers currently being administered to patients.
Introduction
Noninvasive imaging modalities are critical tools used in the management of cancer patients. Anatomical-based imaging modalities such as the computed tomography (CT) scan allow for detailed observation of physical structures based on differences in density. Tumors can exhibit an altered density as compared to surrounding normal tissues, thus making CT scans well suited for oncologic imaging. However, not all tumors exhibit density differences from the surrounding tissues making them refractory to imaging by CT. In addition, the goals of detecting tumors at earlier stages and differentiating between tumor and normal tissues based on cellular and molecular alterations have driven the development of molecular imaging modalities such as positron emission tomography (PET) and others. PET couples the physics of positron emitting radioisotopes with the biological properties of radiolabeled molecules to noninvasively image tumors based on defined molecular characteristics. The most widely used PET radiotracer, 2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG), exploits the Warburg effect [1, 2] , the transition seen in most tumors to a glucose-dependent phenotype, and preferentially accumulates in tumor. Therefore, FDG-PET measures metabolic activity as a surrogate for malignant activity. In recent years, our depth of understanding around the molecular factors that drive cancer formation and progression has increased dramatically. This, in turn, has led to the development of a host of new small molecule inhibitors and antibody therapies for Electronic supplementary material The online version of this article (doi:10.1007/s13277-012-0361-z) contains supplementary material, which is available to authorized users.
treating patients with defined subtypes of cancer. The mechanisms of action by which these targeted therapies work necessitate the development of biomarker and/or imagingbased approaches to stratify patients based on predicted response.
The importance of patient stratification is exemplified by HER2-positive breast cancer (BrCa) and the clinical impact of the HER2-targeted agents. Consistent with the important role that HER2 plays in tissue development and homeostasis [3] , overexpression of the receptor tyrosine kinase, which is seen in approximately 20-30% of all BrCa, causes disregulated signaling downstream of the receptor and leads to an aggressive subtype of BrCa that is associated with poor clinical outcome and high risk of relapse [4] . The anti-HER2 monoclonal antibody (mAb), trastuzumab, blocks HER2-dependent signaling [5] , and its use is associated with improved patient outcome in both the metastatic and adjuvant settings [6, 7] . Eligibility for trastuzumab therapy is based on measurement of HER2 overexpression either at the protein level by immunohistochemical staining or gene amplification via fluorescence in situ hybridization techniques in biopsied tumor tissue. Despite overexpressing HER2, less than 35% of patients in metastatic setting respond to trastuzumab treatment and many that initially respond go on to develop resistance [8, 9] . In addition, preclinical data suggest that trastuzumab treatment could enhance chemosensitivity in defined patient populations, even in the absence of HER2 overexpression. Thus, the ability to either monitor for intrinsic and acquired resistance or predict response to a targeted therapy is of clinical importance. The noninvasive nature and whole body images obtainable with PET, coupled with radiotracers capable of detecting changes at the molecular level, make it well suited for this role.
PET imaging with antibody-based radiotracers represents a promising approach for detecting biomarkers and monitoring changes to biomarker expression that may correlate with response to therapy. Currently, IgG and Fab' fragments of four radiolabeled murine mAbs that are specific for tumor-associated glycoprotein 72, prostate-specific membrane antigen, carcinoembyonic antigen (CEA), and epithelial cell adhesion molecule have been approved by the FDA for use as imaging agents [10, 11] . Radiolabeled trastuzumab is also being evaluated as an immunoPET agent in multiple phase I trials. These agents accumulate to high levels in tumor but the prolonged serum half-life of mAbs, although well suited for use as therapeutics, limits their function as immunoPET radiotracers by increasing the time necessary to achieve sufficient image contrast and potentially leading to unacceptable levels of normal tissue irradiation. This is exemplified by the extensive blood pool levels of 89 Zr-DFO-trastuzumab seen in appropriately dosed patients at 1-2 days post-injection. Optimal imaging in these patients was determined to be 4-5 days post-injection and resulted in high spatial resolution images with good signal to background ratios [12] . Therefore, optimizing the pharmacokinetic (PK) and tumor targeting properties of engineered antibodies to obtain rapid tumor to background contrast, while maintaining sufficient levels of tumor uptake for detection, is a key step in enhancing the clinical utility of antibody-based radiotracers. We, and others, have demonstrated that the clearance properties of genetically engineered antibody fragments are well suited for use as PET radiotracers [13] [14] [15] [16] . Our efforts to develop a HER2-targeted radiotracer have focused on the use of a genetically engineered single chain Fv (scFv)-based antibody molecule called C6.5 diabody [16] [17] [18] . When radiolabeled with Iodine-124 ( 124 I), the C6.5db is capable of effectively imaging HER2-positive xenografts in our preclinical models, and uptake of the radiotracer has been shown to correlate to antigen density on the tumor surface [16] .
In this work, we report the expression of the C6.5db in the methylotrophic yeast strain Pichia pastoris (P-C6.5db) and detail how expression in P. pastoris impacts on the function of the antibody as a PET radiotracer in our preclinical model. In contrast to the C6.5db produced in the Escherichia coli expression system (E-C6.5db) that we described previously, the expression of recombinant proteins in P. pastoris is anticipated to result in glycosylation with branched mannose structures that are not typical of proteins produced in mammalian cells and promote rapid systemic clearance [19, 20] . In the case of antibodies, this can alter their PK and tumor targeting properties [21, 22] . We report the results of studies that evaluate how PK and tumor targeting of P-C6.5db compared to that of E-C6.5db and impacts on the expected dosimetry associated with the two compounds.
Materials and methods
Construction of a C6.5db P. pastoris expression strain
The coding region for the C6.5db was amplified from pSYN-C6.5db [18] by polymerase chain reaction with the primers GA331 (5′<GAAGCTGCAGGTCAGGTGCAGCTGTTG CAGTC>3′) and GA332 (5′<ACTCGAGTTAGCTAAT TAATGGTGATGATGGTGATGACCTAGGACGGT CAGCTTGGT>3′). The resulting PstI/XhoI fragment encoded the C6.5db with a C-terminal 6X-His purification tag and stop codons in all three reading frames. The PstI/XhoI fragment was cloned into PstI/XhoI sites of pPICZαB (cat # V190-20, Invitrogen) to create a translational fusion with the vector-encoded α-factor signal sequence that is cleaved during secretion. A sequence confirmed pPICZαB::C6.5db plasmid was linearized within the AOX1 promoter by digesting with SacI and transformed via electroporation into the X33 strain of P. pastoris (Invitrogen) (25 μF, 0.54 kV, 15 ms pulse). Cells were allowed to recover for 1 h and plated on YPD (1% yeast extract, 2% peptone, 2% dextrose, and 2% agar) plates containing either 0 or 50 μg/mL of Zeocin (cat # R25001, Invitrogen) as a selection reagent. Transformants from the 50-μg/mL selection plates were subcloned, and isolated colonies were tested for expression. The identified high-expressing clone was used for scaleup production in a BioFlo3000 fermentor (New Brusnwick) equipped with dissolved oxygen (Metler Toledo) and pH (Metler Toledo) probes. Fermentation was carried out according to the protocol outlined by Tolner et al. [23] . The cells were grown in YPD+50 μg/mL Zeocin at 30°C to an OD 600 014.2, diluted 100-fold into 200 mL of minimal fermentation media [per liter, 5% glycerol (v/v), 0.9 g CaSO 4 , 14.67 g K 2 SO 4 , 11.67 g MgSO 4 ·7H20, 9 g (NH 4 ) 2 SO 4 , PTM1 trace element solution], and grown for 17 h in a 2-L shake flask. The production culture was inoculated (approx 4 L), and biomass was generated for 25 h followed by a limited methanol feed to induce protein expression. Media was maintained at pH 6.5 and 40% dissolved O 2 throughout the 24-h induction phase. The cells were harvested by centrifugation and supernatants were filtered through a Buchner funnel, brought to 5 mM imidazole, and purified by immobilized metal ion chromatography (IMAC) using Ni-NTA agarose (cat # 30230, Qiagen). C6.5db was eluted from the Ni-NTA agarose matrix using 200 mM imidazole agarose and subjected to high performance liquid chromatography size-exclusion chromatography over a Superdex 75 column (GE Healthcare). Protein was stored at −80°C at a concentration of 0.5 mg/mL in PBS containing 10% glycerol until ready for use.
The plasmid pSYN::C6.5db was transformed into TG1 E. coli, and protein was expressed in shake-flasks. C6.5db was isolated from the periplasmic space and purified by sequential IMAC and size exclusion chromatography as previously described [18] . Protein was stored at −80°C at 0.5 mg/mL in PBS containing 10% glycerol until ready for use.
Binding analysis of C6.5db constructs Binding characteristics of E-C6.5db and P-C6.5db were compared by surface plasmon resonance using a BIAcore 1000 instrument. Briefly, 230 response units (RU) of HER2 extracellular domain (ECD) [24] were coupled to CM5 sensor chips (GE Life Sciences, cat # BR-1000-12) via amine-based coupling using EDC/NHS. E-C6.5db and P-C6.5db at 0, 100, and 500 nM were flowed over both the HER2 and a control sensor surface at a rate of 40 μL/min and regenerated with sequential pulses of 2 M glycine (pH 2) and 1 M triethanolamine (pH 10). Subtracted data were evaluated using a 1:1 Langmuir binding model using the BIAevaluation 3.2 (GE Life Sciences). Radioiodination P. pastoris and E. coli that produced C6.5db were radioiodinated with Na 125 I (cat # NEZ033H, DuPont NEN) or Na 124 I (RITVERC Isotope Products, St. Petersburg Russia) using Iodogen-coated glass beads as described in Robinson et al. [18] . Immunoreactivity of the radiolabeled preparations were assayed by live cell binding assays with SK-OV-3 cells under conditions of antigen excess as described previously [25] .
Biodistribution and dosimetry
Blood and whole body clearance as well as biodistribution of the C6.5db-based radiotracers in severe combined immunodeficient (SCID) mice was determined as previously described [18] . PET imaging was performed on a Siemens Biograph 16 TruePoint PET/CT scanner (Siemens Healthcare, Malvern, PA, USA). The mice were kept anesthetized with Isoflurane in an induction chamber on the patient bed. A low-dose helical CT was performed with the following parameters: 130 kV, 24 mAs, 0.6-s rotation, 16×0.6-mm collimation, pitch of 1, and reconstructed at 2-mm-slice thickness, and 1-mm interval. Then a PET emission scan was acquired for 10 min in 3D mode. The PET/CT scans were performed at 2, 24, 48, 120, and 192 h after injection. The PET images were reconstructed using CT for attenuation correction, including corrections for random coincidences, and scatter on a 336×336 matrix for a 63-cm diameter field view, with manufacturer supplied software using Truex algorithm with two iterations and 21 subsets, and 2-mm FWHM post-processing filter.
The PET and CT images were fused using MIM software version 5.1 (MIM Software Inc., Cleveland, OH, USA). Uptakes were determined by drawing volumes of interest (VOIs) directly on the PET images for tumor, and the following organs visualized above background activity levels are: thyroid, stomach, liver, heart, and bladder. Percent injected dose (ID) was calculated for tumors and the different organs at each time point using the integrated activity within the VOIs. The total measured activity in the mouse was also determined by summing all the observed activity in the mouse PET images at each time point. By fitting decaycorrected total activity in the mouse to exponential decay, the half-time for biological decay was determined for each mouse.
We used the OLINDA/EXM software (version 1.1) (Vanderbilt University, Nashville, TN, USA) for determining the radiation doses from the imaging compounds [26] . The percent ID for each organ for each time point was entered into the program, and the data were fitted to exponentials or sum of exponentials to determine the number of disintegrations per unit of administered activity, usually referred to as residence time. Bladder voiding model of 1-and 4.8-h voiding intervals were used to determine the residence time for the bladder. Organ doses and the effective doses were scaled using the standard adult male model in the software.
Results
Expression of C6.5db in E. coli and P. pastoris systems The C6.5db was successfully expressed as a fully functional, secreted protein in both the E. coli expression system (E-C6.5db), as previously described [27] , and in the P. pastoris (P-C6.5db) expression system as outlined by Tolner et al. [23] . For this study, the P-C6.5db was expressed using the plasmid pPICZαB::C6.5db and secreted into the media guided by the α-factor secretion signal that is proteolytically cleaved upon secretion. Purification of E-C6.5db and P-C6.5db by sequential Ni affinity and size exclusion chromatography resulted in a major species that eluted in agreement with the predicted 54 kDa molecular weight of the noncovalent dimer (data not shown). SDS-PAGE analysis of the purified proteins demonstrated that both migrated at a size (~27 kDa) consistent with the predicted behavior of the denatured C6.5db (Fig. 1a) . Interestingly, P-C6.5db migration was slightly retarded as compared to P-C6.5db, consistent with it being glycosylated. In addition, the P-C6.5db routinely appeared more resistant to denaturation as seen by the presence of higher molecular weight, presumed dimers on the SDA-PAGE analysis. The 28 mg C6.5db/L of culture media yields obtained using the P. pastoris system compares very favorably to the 1-3-mg/L yields obtained in the E. coli expression [27] .
Consistent with the prediction that P-C6.5db would be glycosylated, Western blot analysis of purified P-C6.5db with Concanavalin A, a lectin with specificity for mainly internal and non-reducing terminal α-mannosyl groups, showed a defined band at the appropriate molecular weight for C6.5db (Fig. 1b) . To determine if glycosylation negatively impacted on the ability of P-C6.5db to bind HER2, its binding was compared to E-C6.5db. As depicted in Fig. 1c , purified E-C6.5db and P-C6.5db exhibited similar binding to HER2 ECD as measured by SPR on a low-density HER2 sensor surface (R max 0150 RU). Within the limits of this experiment, analysis of the binding data generated with E-C6.5db and P-C6.5db using a 1:1 Langmuir mode suggests that E-C6.5db and P-C6.5db have similar binding affinities. [28] . This data support the idea that glycosylation associated with expression in the P. pastoris system (Fig. 1b) did not impact negatively on the ability of the diabody to bind its target antigen.
Biodistribution and pharmacokinetics of E. coli-and P. pastoris-produced C6.5db
Biodistribution and PET imaging studies were carried out with both E-C6.5db and P-C6.5db antibody that had been radiolabeled with either 124 I or 125 I as appropriate. In all cases, radiotracers were at specific activities of 37 kBq/μg and radiochemical purity of 95-99%. Immunoreactivity of radioiodinated proteins was approximately 85% for 125 Ilabeled proteins with 124 I-labeled proteins ranging from 31% to 77% for E. coli and 50-60% for P. pastoris. Although a single preparation of 124 I-E-C6.5db had low immunoreactivity (31%) as measured by in vitro binding studies, possibly due to radiolysis, the in vivo behavior of the radiotracer was consistent with that of higher activity preps and therefore considered representative in this analysis.
Consistent with the predicted impact of glycosylation in the P. pastoris expression system, P-C6.5db demonstrated a more rapid systemic clearance than E-C6.5db in SCID mice bearing HER2-positive SK-OV-3 tumor xenografts (Fig. 2) . At 4 h post-injection, a significantly lower (P<0.001) level of P-C6.5db (11.3±0.4% of initial dose) remained in circulation as compared to E-C6.5db (69.9±7%). This is despite a similar level of whole body retention seen with both radiotracers at 4 h post-injection (85.7±2 P-C6.5db vs. 89.7±1.8 E-C6.5db; P00.18). By 24 h, both blood levels (0.6±0.1 vs. 1.3±0.2, P00.01) and whole body levels (5.0± 0.3 vs. 10.2±1.9, P00.03) of P-C6.5db were approximately half than that are seen with E-C6.5db. Although absolute values were even lower at 48 h, the trends for both blood and whole body levels continued and maintained statistical significance (P < 0.01). The more rapid clearance of P-C6.5db from circulation correlated with a statistically significant decrease in overall tumor uptake at 4 h postinjection (Table 1) . At 4 h post-injection, P-C6.5db was retained in tumors at only 5.08±0.6%ID/g as compared to E-C6.5db that was present at 7.8 ± 0.5%ID/g (P ≤ 0.01). Statistically significant differences (P≤0.03) in tumor targeting levels were maintained between P-C6.5db and E-C6.5db at each time point analyzed with a 1.9±0.2 vs. 3.8 ±0.7%ID/g, respectively at 24 h, and 1.1±0.1 vs. 1.8±0.1% ID/g, respectively at 48 h. The rapid systemic clearance of P-C6.5db is predicted to occur because of the contributions of hepatic clearance routes. Interestingly, liver activity levels seen with P-C6.5db were lower than observed with E-C6.5db at both 4 and 24 h post-injection (P<0.03).
Despite the lower overall tumor uptake seen with P-C6.5db, which could have a deleterious impact on its efficacy as a radiotracer, the more rapid blood clearance resulted in a trend toward higher tumor/blood values for P-C6.5db than E-C6.5db at all time points analyzed ( Table 2) . Although this trend failed to reach significance (P00.18), the high tumor/ blood levels achievable with P-C6.5db, it reached approximately 12:1 at 24 h and 36:1 at 48 h, provided the rationale for evaluating P-C6.5db as a PET radiotracer. As seen in Fig. 3 , P-C6.5db was capable of effectively imaging HER2-positive tumors in our preclinical model. Dosimetry time course of E. coli-and P. pastoris-produced C6.5db measured by PET The ability of P-C6.5db to effectively image HER2-positive xenografts coupled with the faster clearance suggested that its use may lead to lower patient exposures than E-C6.5db while providing equivalent, or better, image contrast. SCID mice bearing SK-OV-3 tumor xenografts were injected with either 124 I-P-C6.5db or 124 I-E-C6.5db and imaged serially over a 192-h time course to perform dosimetry calculations. Selected slices of coronal views of PET/CT fusion image are shown for one representative mouse from each group at each time point analyzed (Fig. 4) . The five time points over 192 h showed typical uptake patterns associated with the targeting and clearance of the C6.5db. In addition to tumor, high uptake was observed in the bladder, stomach, and thyroid, consistent with renal clearance and release of free iodine upon catabolism of the antibody [27] . Uptake of E-C6.5db and P-C6.5db in the liver, based on dosimetry studies (Table 3 ), demonstrated that the percentage of At subsequent time points, the level of P-C6.5db in the liver trended higher than levels observed with E-C6.5db, reaching the level of statistical significance by 120 h (P00.05). Immediately following the final imaging time point, the mice were euthanized and dissected so that physical measurements of activity in their organs could be taken. As depicted in Table 4 , uptake in tumor and liver as measured directly by both imaging and biodistribution correlated well. The correlation was less robust in the stomach and heart where uptake calculated by imaging was higher and presumably due to the process of emptying the stomach contents and blood from the heart prior to counting during the biodistribution. Likewise, conversion of standardized tumor uptake data of 125 I-labeled compounds from percent ID per gram (Table 1) to percent ID by taking into account average tumor volume demonstrates that 1.3%ID and 0.8% ID of 125 I-E-C6.5db was retained in tumors at 24 and 48 h post-injection, respectively. At the same time points, 0.8% ID and 0.6%ID of 125 I-P-C6.5db were retained in tumor. These values correspond well to the levels of 124 I-labeled antibodies that were measured to be in tumor during the dosimetry studies (Table 3) Average organ activity for mice injected with P. pastoris-vs. E. coli-produced 124 I-C6.5 diabody. 124 I-C6.5db was administered to SCID mice bearing SK-OV-3 tumor xenografts via tail vein injection, and mice were imaged at 2, 24, 48, 120, and 192 h p.i. on a clinical PET/CT scanner. All values are decay corrected. Standard error (±SEM) is given following each average organ activity targeting observed between different experiments with both P-C6.5db and E-C6.5db. In addition, activity levels measured by imaging in a microsphere phantom study, performed at lesion to background levels that bracket those seen in our animal model, demonstrate a good correlation with known activity levels in the spheres (see Supplemental Table 1 ).
The average percent ID data for a series of 24 tissues for each group of mice was extrapolated to the human equivalent percent ID to calculate the total effective dose of an adult male using the OLINDA/EXM software assuming both a 4.8-and 1.0-h bladder voiding model. The five organs with the highest average effective dose equivalents in each model are displayed in Table 5 . In all cases the highest dose was to the thyroid, consistent with the use of the iodogen-based method for labeling of the radiotracers and release of free radioiodine upon internalization and degradation of the radiotracer. Use of the 4.8-h bladder voiding model results in an average effective dose of 0.36±0.13 and 0.35±0.08 mSv/MBq for E-C6.5db and P-C6.5db, respectively. The use of a 1-h bladder voiding model lowered the average effective doses to 0.31±0.13 and 0.30±0.08 mSv/MBq, respectively. This data suggest that radiation dose from P-C6.5db and E-C6.5db are similar and can potentially be reduced slightly by frequent voiding.
Discussion
The need for methods to quantify therapeutic biomarkers has increased concomitantly with the development and use of targeted therapies to treat cancer. PET is a quantitative imaging modality that exploits biochemical processes to image tumors. Thus, it provides the potential to gain more information related to therapeutic efficacy than standard anatomical-based modalities, which rely on structural changes assessed in response to standards such as response evaluation criteria in solid tumors. In addition, biochemical changes in response to therapy are often manifested well in advance of structural changes providing a more rapid evaluation of therapeutic efficacy. This is exemplified by the use of FDG-PET vs. CT scans for monitoring the response of gastrointestinal stromal tumors to imatinib mesylate. A decrease in the metabolic activity measured by standard uptake value posttreatment, as compared to pretreatment levels, was superior to CT at detecting early response to therapy and was also associated with a longer progression-free survival [29, 30] . A large number of radiotracers capable of measuring different aspects of tumor biology, which are applicable to a wide variety of cancers, are currently at various stages of clinical development [31, 32] . Included among these radiotracers are the compounds fluorothymidine to measure proliferation rate [33] and fluoromisonidazole to measure hypoxia [34] . Fluorinated versions of the annexin V protein are also being developed to measure apoptosis [35] . Other compounds, such as the fluorinated analog of the androgen receptor-binding ligand (fluorodihydrotestosterone) [36] [37] [38] , are being developed to monitor characteristics specific to defined subtypes of tumors.
We, and others, have hypothesized that antibody-based radiotracers can be used to effectively image and phenotype tumors based on antigen expression and thereby help guide therapy decisions. In previous work, we demonstrated that the anti-HER2-engineered antibody fragment C6.5db is capable of accumulating in tumors at sufficiently high levels with appropriate contrast to normal tissue to be an effective PET radiotracer for the detection of HER2-positive tumors in preclinical models [16, 27] . Image quality, in terms of absolute tumor uptake and tumor to background signal, needs to be balanced with other considerations, such as the total radiation exposure received by the patient during the scan, when designing novel radiotracers. In an effort to further optimize the C6.5db for translation toward clinical evaluation, we hypothesized that accelerating the systemic clearance of the C6.5db may increase its utility as a radiotracer by improving the tumor to background ratios achievable with the radiotracer while retaining sufficient absolute uptake of the radiotracer in tumor to allow for efficient tumor detection. This in turn would have the potential to decrease the total radiation exposure received by the patient. In this work, we examined the impact associated with altering the PK of the radiotracer by producing the C6.5db in two distinct expression systems. Modification of the PK was evaluated in the context of overall tumor targeting and the internal radiation dosimetry, as calculated through use of the OLINDA software package. Here, PK modulation was achieved by fermentation-based expression of C6.5db in P. pastoris, a system that has been used for the production of a number of therapeutic proteins, including antibodies [23, [39] [40] [41] . P. pastoris modify proteins with both N-and O-linked glyscosylation [20, 40] that are nonmammalian in structure, resulting in rapid systemic clearance via pattern recognition mannose receptors (MR) that are present on a number of cell types, including liver endothelial cells [42] . This is exemplified by the rapid, MR-based clearance of glycosylated MFECP1, an antibody-enzyme fusion, as compared to non-glyscosylated MFECP1 that leads to a 375 times lower level of enzyme activity in serum 6 h after injection [19, 39, 43] . Although not formally tested, we hypothesize that the clearance difference seen between E-C6.5db and P-C6.5db was due to rapid MR-based clearance through the liver, which is likely taking place even before the first time points analyzed in this study. Consistent with this hypothesis, the C6.5db has the potential for being glycosylated. It contains five Asn residues, one within the V h and four within the V l domains. However, none of these are found within the context of the Asn-X-S/T consensus motif for N-linked glycosylation [44] and are not predicted to be glycosylated by the web-based analysis software NetNGly1.0 (http://www.cbs.dtu.dk/services/NetN Glyc). Likewise C6.5db contains a total of 53 Ser and Thr residues spread across both domains of the protein. NetOGly3.1 predicts that four of these residues, Thr141, Ser145, Thr155, and Thr206, are potential sites for glycosylation (http:// www.cbs.dtu.dk/services/NetNGlyc). Although we did not identify defined sites of glycosylation on P-C6.5db, binding by Concanavalin A and the rapid clearance, together, point to the antibody being glycosylated in this system. Importantly, in vitro binding activities suggest that glycosylation does not impact on the antigen-binding properties of the antibody. Further analysis to map the sites of modification is warranted.
Imaging with both E-C6.5db and P-C6.5db resulted in clear visualization of the tumor xenografts by at least 24 h post-injection in our preclinical model of HER2-positive cancer. Despite the fact that P-C6.5db cleared more rapidly from the circulation and exhibited lower overall tumor uptake, it displayed a trend towards higher tumor to background ratios than those observed with E-C6.5db. By 24 h, both radiotracers compared favorably to the tumor to background ratios achieved with 89 Zr-trastuzumab at 144 h in preclinical imaging studies [45] . When translated into patients, 89 Zr-DFOtrastuzumab reached a maximum tumor to background ratio of 7.6 at 144 h [12] . Rapid generation of high tumor to background ratios suggest that both P-C6.5db and E-C6.5db could function as effective radiotracers in contrast to radiolabeled trastuzumab while potentially limiting patient exposure to radiation as the radioisotope is rapidly removed from the body. Radiolabeled trastuzumab suffers from the additional complication that it binds to the same epitope as trastuzumab and therefore has different targeting properties in the setting of trastuzumab therapy [12] due to receptor saturation. In contrast, it has been previously demonstrated that C6.5db does not compete at the binding site occupied by trastuzumab, making it a potential candidate for concurrent use in monitoring trastuzumab therapy [16] .
Imaging studies carried out under Radioactive Drug Research Committee approval limit patient exposure to 30 mSv. This is important in the context of 124 I-based PET imaging. The positron emission and multiple gamma emissions I-NaI (6.50 mSv/MBq) [48] . Our image-based quantification is also supported by the correlation between the 192-h image and biodistribution uptake data obtained in this study (Table 4) . In biodistribution studies such as ours, volume integrated activity in organs are used to estimate the uptake in the organs. Phantom studies have shown this method results in a much smaller partial volume effect (Supplemental Table 1 ) in comparison to using peak activity per unit volume to estimate the activity in lesions [49] . Another source of error in estimating human doses is the scaling processes used to estimate human dosimetry from murine data. However, we hypothesize that both of these effects would impact both radiotracers equivalently, thus allowing for a direct comparison between the two. Absolute determination of dosimetry will require clinical translation of these agents.
In conclusion, the anti-HER2 engineered antibody fragment C6.5db produced in either the P. pastoris or E. coli expression systems can function effectively as a PET radiotracer when radiolabeled with 124 I. Selection of expression system for translation of this radiotracer into the clinic will require an evaluation of the benefits and drawbacks of each system. Presumed differences in clearance mechanisms (liver vs. kidney) and relative radiosensitivity of those organs may dictate expression system use. In addition, altered clearance routes may result in unsatisfactory background signal in organs that are known sites of metastasis for certain diseases.
